ImmunityBio, Inc. IBRX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s enterprise value?
- ImmunityBio, Inc. (IBRX) reported enterprise value of $8.16B in Q1 2026.
- How has ImmunityBio, Inc.'s enterprise value changed year-over-year?
- ImmunityBio, Inc.'s enterprise value increased by 186.9% year-over-year, from $2.85B to $8.16B.
- What is the long-term trend for ImmunityBio, Inc.'s enterprise value?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s enterprise value has grown at a -15.2% compound annual growth rate (CAGR), from $5.08B to $2.23B.
- What does enterprise value mean?
- What it would cost to buy the entire business, debt included and cash netted out.
- How do you interpret enterprise value?
- The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
- How does enterprise value compare across companies?
- Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.